Elevated glucose metabolism driving pro-inflammatory response in B cells contributes to the progression of type 1 diabetes

Copyright © 2023 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 255(2023) vom: 01. Okt., Seite 109729
1. Verfasser: Li, Zeying (VerfasserIn)
Weitere Verfasser: Zhao, Mingjiu, Li, Jingyue, Luo, Wenjun, Huang, Juan, Huang, Gan, Xie, Zhiguo, Xiao, Yang, Huang, Jiaqi, Li, Xia, Zhao, Bin, Zhou, Zhiguang
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Autoimmunity B cells Glucose metabolism LADA Metabolic inhibitors Type 1 diabetes Proto-Oncogene Proteins c-myc Cytokines mehr... Glucose IY9XDZ35W2
LEADER 01000naa a22002652 4500
001 NLM360622968
003 DE-627
005 20231226083416.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2023.109729  |2 doi 
028 5 2 |a pubmed24n1202.xml 
035 |a (DE-627)NLM360622968 
035 |a (NLM)37562723 
035 |a (PII)S1521-6616(23)00492-8 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Li, Zeying  |e verfasserin  |4 aut 
245 1 0 |a Elevated glucose metabolism driving pro-inflammatory response in B cells contributes to the progression of type 1 diabetes 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 02.10.2023 
500 |a Date Revised 02.10.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2023 Elsevier Inc. All rights reserved. 
520 |a Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune system's failure to maintain self-tolerance, resulting in the autoimmune destruction of pancreatic beta cells. Although T1D has conventionally been viewed as a T-cell-dominant disease, recent research has emphasized the contribution of B cells in the onset of the disease. However, the mechanism underlying aberrant B cell responses remains unknown. B cell metabolism is a crucial prerequisite for B cell function and the development of adaptive immune responses. Here, we investigated the metabolic features of B cells, first in a cross-sectional cohort and subsequently in non-obese diabetic (NOD) mice, and revealed that there is an increased frequency of high-glucose-avidity (2-NBDGhigh) B cell population that may contribute to T1D progression. Further characterization of the metabolic, transcriptional and functional phenotype of B cells in NOD mice found that elevated glucose avidity is associated with a greater capacity for co-stimulation, proliferation and inflammatory cytokine production. Mechanistically, elevated Myc signaling orchestrated the glucose metabolism and the pro-inflammatory response of B cells in T1D. In vitro experiments demonstrated that pharmacological inhibition of glucose metabolism using metformin and 2-DG reduced pro-inflammatory cytokine production and B cell proliferation. Moreover, the combination of these inhibitors successfully delayed insulitis development, onset of diabetes, and improved high blood glucose levels in streptozotocin (STZ)-induced diabetic mice model. Taken together, our work has uncovered these high-glucose-avidity B cells as novel adjuvant diagnostic and therapeutic targets for T1D 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Autoimmunity 
650 4 |a B cells 
650 4 |a Glucose metabolism 
650 4 |a LADA 
650 4 |a Metabolic inhibitors 
650 4 |a Type 1 diabetes 
650 7 |a Proto-Oncogene Proteins c-myc  |2 NLM 
650 7 |a Cytokines  |2 NLM 
650 7 |a Glucose  |2 NLM 
650 7 |a IY9XDZ35W2  |2 NLM 
700 1 |a Zhao, Mingjiu  |e verfasserin  |4 aut 
700 1 |a Li, Jingyue  |e verfasserin  |4 aut 
700 1 |a Luo, Wenjun  |e verfasserin  |4 aut 
700 1 |a Huang, Juan  |e verfasserin  |4 aut 
700 1 |a Huang, Gan  |e verfasserin  |4 aut 
700 1 |a Xie, Zhiguo  |e verfasserin  |4 aut 
700 1 |a Xiao, Yang  |e verfasserin  |4 aut 
700 1 |a Huang, Jiaqi  |e verfasserin  |4 aut 
700 1 |a Li, Xia  |e verfasserin  |4 aut 
700 1 |a Zhao, Bin  |e verfasserin  |4 aut 
700 1 |a Zhou, Zhiguang  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 255(2023) vom: 01. Okt., Seite 109729  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:255  |g year:2023  |g day:01  |g month:10  |g pages:109729 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2023.109729  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 255  |j 2023  |b 01  |c 10  |h 109729